Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma

Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma: A Multicenter Retrospective Study

This multicenter retrospective study evaluates preoperative ROS1-TKI therapy in patients with ROS1 fusion-positive locally advanced lung adenocarcinoma. Patients who received ROS1-TKI therapy before surgical resection were retrospectively identified from four tertiary hospitals in China. The study describes clinicopathological characteristics, radiographic response, treatment-related adverse events, surgical outcomes, pathological response, and follow-up outcomes.

Inclusion Criteria:

1. Age 18 years or older.
2. Histologically confirmed lung adenocarcinoma.
3. ROS1 fusion positivity confirmed in tumor tissue at the DNA or RNA level.
4. M0 disease at baseline.
5. Receipt of targeted therapy before surgery.
6. Surgical resection performed after ROS1-TKI therapy.
7. Availability of comprehensive clinical, radiographic, treatment, surgical, pathological, and follow-up data.

Exclusion Criteria:

1. Baseline M1 disease.
2. Receipt of radiotherapy or immunotherapy before ROS1-TKI therapy.
3. No surgical resection after ROS1-TKI therapy.
4. Lack of essential data for endpoint evaluation.